Literature DB >> 30407885

Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.

Guru Subramanian Guru Murthy1, Satish Kumar Pondaiah2, Sameem Abedin1, Ehab Atallah1.   

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is a curable malignancy in the pediatric population. However, population-level data on its incidence and outcomes among adults is sparse. Using SEER database, we identified 1141 patients aged ≥20 years with pathologically confirmed T-ALL diagnosed between the years 2001 and 2014 and actively followed. Incidence of T-ALL was 0.13 cases/100,000 population with significant variations by age, gender, race, and period. The 5-year overall survival (OS) declined significantly with increasing age (age <40, 51.9%; age 40-59, 37.3%; age 60-79, 19.2%; age ≥80, 0%; p < .001) and varied by race (whites - 45.7%, blacks - 25.1%, others - 40.3%; p < .001). Over time, OS has improved significantly in patients <60 years (2001-2007, 42.8% vs 2008-2014, 53.1%; p = .005), but not in patients older than 60 years (2001-2007, 18% vs 2008-2014, 22.8%; p = .71), highlighting the need for effective and safe treatments in this population.

Entities:  

Keywords:  Leukemia; SEER; T-lymphocytic; incidence; survival

Year:  2018        PMID: 30407885     DOI: 10.1080/10428194.2018.1522442

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.

Authors:  Mengping Xi; Shanshan Guo; Caicike Bayin; Sophie Rousseaux; Saadi Khochbin; Jian-Qing Mi; Jin Wang; Lijun Peng; Florent Chuffart; Ekaterina Bourova-Flin
Journal:  Front Med       Date:  2021-10-20       Impact factor: 9.927

Review 2.  Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL).

Authors:  Eulàlia Genescà; Celia González-Gil
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 3.  State-of-Art of Cellular Therapy for Acute Leukemia.

Authors:  Jong-Bok Lee; Daniel Vasic; Hyeonjeong Kang; Karen Kai-Lin Fang; Li Zhang
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

4.  Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors:  Lina Driouk; Joanina K Gicobi; Yusuke Kamihara; Kayleigh Rutherford; Glenn Dranoff; Jerome Ritz; Susanne H C Baumeister
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

Review 5.  Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies.

Authors:  Chun-Fung Sin; Pui-Hei Marcus Man
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

Review 6.  Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.

Authors:  Omar Castaneda Puglianini; Nikolaos Papadantonakis
Journal:  Ther Adv Hematol       Date:  2020-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.